NewsRoom Articles - Page 111 of 222

ThursdayAug 11, 2022 9:30 am

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers Odyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts and allow interested investors to access information regarding the company The website redesign follows on the company’s name change earlier this year to similarly improve the expression of its brand identity Medical technology…

WednesdayAug 10, 2022 2:10 pm

Brain Fingerprinting Adolescents Could Predict Future Mental-Health Issues

New research has demonstrated how the uniqueness of the brain of an adolescent may forecast mental-health outcomes. For this study, researchers focused on the adolescent brain, as changes during this period are dynamic and rapid and help form every individual’s uniqueness. Additionally, most mental-health conditions show up during this period, with more than one-half occurring by the time a child is 14 and about three-quarters of mental-health conditions occurring by the time an individual is 25 years of age. The researchers hypothesize that observing and tracking changes in the brain as they occur may make it easier to tackle emerging…

TuesdayAug 09, 2022 1:36 pm

Research Shows Access to Health Insurance Invaluable in Early Cancer Diagnosis

Cancer is the second most common cause of death in the United States, affecting nearly two million people yearly and taking more than one-half a million lives every year. Almost one-half of the people who suffer from cancer are diagnosed with the deadly condition late. More often than not, late-stage diagnoses significantly limit the effectiveness of treatment and reduce chances of survival. Research by the UK government’s director of cancer services shows that up to 10,000 people die every year due to late-stage cancer diagnoses According to a study published in the “Cancer” journal, pediatric patients from racial and ethnic…

MondayAug 08, 2022 2:01 pm

Researchers Leverage Apps in Treatment of TBI

A 1999 report to Congress stated that traumatic brain injuries (TBIs) are the top cause of disability and death in children and young adults in the United States. Two decades later, an estimated 2.8 million Americans sustain TBIs every year resulting in 280,000 hospitalizations and 50,000 fatalities. Depending on the region of the brain that received trauma, some patients have to deal with long-term effects, including speech difficulties, trouble with logic and understanding others, and apraxia. The cognitive deficiencies caused by TBIs can result in reduced brain activity and significantly impact the patient’s way of life. Although it is virtually…

FridayAug 05, 2022 10:15 am

Combining Immunotherapy with Anti-Rejection Drugs Can Treat Cancer, Prevent Kidney Transplant Rejection

Most kidney transplant patients usually stop taking their immunosuppressive drugs before starting cancer immunotherapy treatment to diminish the chances of their immune systems attacking the transplanted organs. However, a new study has found that combining standard antirejection medication and immune checkpoint inhibitors may benefit kidney transplant patients who suffer from terminal cancer. Immune checkpoint inhibitors are drugs designed to block checkpoints, which are proteins that prevent immune responses in the body from being too strong. Checkpoints also prevent T-cells from eliminating cancer cells. Blocking these checkpoints allows T-cells to eradicate cancer cells more effectively. The study’s objective was to look…

ThursdayAug 04, 2022 12:16 pm

Study Finds That Ketogenic Diet May Help Patients with Brain Cancer

New research has found that a ketogenic diet is feasible and safe for individuals with astrocytomas. A ketogenic diet is low in carbohydrates and high in fat. Astrocytomas are brain tumors that usually begin in cells known as astrocytes, which support nerve cells and occur in the brain or spinal cord. For their study, the researchers recruited 25 patients with astrocytomas who were each required to follow the Atkins diet and fast intermittently during an eight-week period. The modified ketogenic diet includes foods such as fish, butter, heavy cream, eggs, leafy green vegetables and bacon. The participants visited a dietician…

ThursdayAug 04, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits Another long-standing concern among service personnel is the treatment of concussive brain injuries Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on…

ThursdayAug 04, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market

CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study — particularly for one who remains cancer-free more than 15 years later CNS is enrolling patients in the United States, Italy, France, Spain, and Switzerland, for the global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a…

WednesdayAug 03, 2022 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership…

WednesdayAug 03, 2022 10:49 am

Research Finds That Tourism, Travel May Boost Mental Health

A new study has suggested that tourism should be viewed as an industry that offers real health benefits, in addition to being viewed as a recreational experience. The study, which was conducted by researchers at the Center for Precision Health at the Edith Cowan University in collaboration with the School of Business and Law, discovered that various aspects of being on holiday could have a positive influence on individuals with mental health conditions. Dr. Jun Wen, the study’s lead researcher, stated that the diverse team of experts on public health, tourism and marketing looked into how tourism could benefit individuals…